News

TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions. The state-of-the-art manufacturing facility will be over 250,000 sq. feet and located across 64 acres in RTP. The site will support cGMP manufacturing of animal component-free, dry powder, and liquid media, adding additional production capacity for FUJIFILM Irvine Scientific of 800,000 Kg/year for dry powder, 3,300,000 L/year for liquid, and

MADISON, Wis., September 15, 2022 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singeç, M.D., as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the Company’s future iPSC technological pipeline. In his role as part of the Company’s executive leadership team, he will also help drive business strategy with the goal of transforming scientific research and healthcare by using iPSC technologies.  “We are thrilled to welcome Dr. Singeç to the FUJIFILM Cellular Dynamics family,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics, Inc. “Dr. Singeç brings over 20 years of experience in cell and molecular biology, and extensive stem cell expertise, which will be instrumental as FUJIFILM Cellular Dynamics expands our application of leading-edge iPSC technologies to continue innovating in this field.” Prior to joining

BILLINGHAM, UNITED KINGDOM, September 22, 2022 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today the start of the expansion of its large-scale microbial manufacturing facility located at the Billingham, UK campus. The company held a small internal ceremony at the site on 6 September 2022. To accommodate the increasing demand for FUJIFILM Diosynth Biotechnologies’ microbial development and manufacturing services, the expansion will include over 1858 square meter (20,000 sq. ft.) of modular clean room space, including two primary recovery and refolding suites, two purification suites and a column packing room. The new space is designed to maximize the emerging SymphonX™[1] technology for clinical and commercial manufacturing. Once the expansion is complete in late 2023/early 2024, the manufacturing capacity of the large-scale microbial production facility will increase by 70%. “Through innovation and the utilization of high-throughput technologies, we

Hillerød, Denmark, September 12, 2022 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, held a groundbreaking ceremony today to celebrate the start of its new expansion project to transform the Denmark site into the largest end-to-end CDMO in Europe[1]. The expansion project will strengthen FUJIFILM Diosynth Biotechnologies’ cell culture manufacturing services in Denmark and create 450 new jobs. Participating in the ceremony were Jeppe Kofod, Danish Minister of Foreign Affairs, Kirsten Jensen, Mayor, Hillerød municipality, Manabu Miyagawa, Japanese Ambassador to Denmark, and Kenji Sukeno, Chairman, Representative Director and Board Chairman, FUJIFILM Holdings Corporation. This expansion is funded by a major capital investment of USD 1.6 billion (11 billion Danish kroner) by FUJIFILM Corporation. The expansion will increase the capacity of the current site by adding 8 x 20,000L bioreactors and two downstream processing streams. When the expansion is completed,

Offering ideal handling viscosity with added confidence from rigorous testing procedures SANTA ANA, Calif., July 26, 2022– FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), today announced the launch of its Heavy Oil for Embryo Culture, a sterile mineral oil with an optimal weight viscosity that provides the ideal balance between ease of use and protection. Common concerns within the IVF Laboratory for embryo development during in vitro culture include media evaporation, changes in osmolality, and pH shifts due to the small volume of media used. Heavy Oil for Embryo Culture addresses those concerns with the ideal viscosity to provide an optimal in vitro environment for embryo development. To ensure the utmost quality, each raw material lot of Heavy Oil for Embryo Culture is validated using FUJIFILM Irvine Scientific’s genetic mouse embryo assay MEGA, a bioassay

TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO). This investment will enhance FUJIFILM Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the United States.  As part of this investment, FUJIFILM Diosynth Biotechnologies is further expanding its capacity to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility.  The additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production complemented by comprehensive drug product and finished goods services. The investment is expected to create approximately 450 jobs. The Denmark facility will be enhanced with

Annual program aims to advance translational medical science research and education CAMBRIDGE, Mass. — FUJIFILM Holdings America Corporation (Fujifilm), today announced that four doctoral students have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS). Since its launch in 2019, the program has now provided 17 fellowships for PhD students who are enrolled at HMS and focused on translational medicine, the process of applying basic research in the laboratory for new therapeutic development. The mission of the program is to equip promising scientists with the specialized skills needed to translate their research findings into next-generation medical solutions for patients. Specifically, the program awards two years of research funding to students from across the nine HMS-based life sciences Ph.D. programs. HMS leadership selects all program beneficiaries. “Taking new therapies from bench to bedside requires exacting work carried out by dedicated and innovative scientific thinkers,” says Yutaka Yamaguchi, general manager, Life

The Company looks to expand the use of AI in efforts to improve IVF success SANTA ANA, Calif., – FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), today announced it has exclusively licensed the intellectual property relating to artificial intelligence (AI) for image-based evaluation of human embryos to improve in-vitro fertilization (IVF) success rates. The technology was developed and patented jointly by investigators from Brigham and Women’s Hospital and Massachusetts General Hospital with expertise in artificial intelligence, biomedical engineering and IVF. Terms of the deal were not disclosed. FUJIFILM Irvine Scientific plans to offer non-exclusive licensing of the technology to companies wishing to advance the use of AI and image-based tools in reproductive healthcare and will immediately be seeking agreements, globally. This image-based technology has the fundamentally enabling advantage of no capital investment while seamlessly merging

Fujifilm-sponsored educational session to spotlight microbiome therapeutics development innovation Cambridge, Mass. – Fujifilm Life Sciences, a portfolio of companies with comprehensive solutions ranging from Bio CDMO services to drug development support, and including induced pluripotent stem cells (iPSCs), cell culture media, and reagents, today announced that it will have a unified presence at BIO2022 (June 13-16) at the San Diego Convention Center in San Diego, California. Fujifilm Life Sciences will showcase each company’s individual unique solutions, explore new business partnerships, and sponsor an interactive panel educational session on microbiome therapy development. “The many and diverse offerings of Fujifilm Life Sciences support and accelerate the discovery, development, manufacturing and commercialization of new therapies,” said Yutaka Yamaguchi, general manager, Life Sciences Business Division, FUJIFILM Corporation; chairman and chief executive officer, FUJIFILM Irvine Scientific, Inc. “As one Fujifilm, BIO2022 gives prospective partners a sense of the synergies and depth of experience Fujifilm can provide

TOKYO ― FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has begun implementation of a phase 2a study in the U.S. to evaluate safety, tolerability, and preliminary efficacy of FF-10832, a liposomal drug candidate, in combination therapy with Merck & Co., Inc., Rahway, N.J., U.S.A.’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for patients with advanced solid tumors. FF-10832 is a liposomal formulation which encapsulates gemcitabine*1, an approved anti-cancer agent indicated for the treatment of a variety of solid tumors. The primary focus of the trial is to establish the safety and tolerability of FF-10832 in combination with KEYTRUDA in patients with advanced solid tumors, and evaluate its preliminary efficacy in non-small cell lung cancer (NSCLC)*2 and urothelial cancer (UC)*3 patients who have progressed after standard therapy, including immune checkpoint inhibitor therapy. This trial will enroll up to 100 patients in two indications (UC and NSCLC) into one